Table 2. Incidence of all treatment-emergent adverse events by subject treatment group.

Treatment	Placebo		SRT2104		SRT2104
			0.5 g/day		2.0 g/day
	(n = 8)		(n = 8)		(n = 9)
Number of subjects experiencing any adverse event	8	(100%)	8	(100%)	9	(100%)
Nervous system disorders
Headache	2	(25%)	5	(63%)	1	(11%)
Lethargy	1	(13%)	1	(13%)	0
Dizziness	0		0		1	(11%)
Migraine	0		1	(13%)	0
Syncope vasovagal	0		0		1	(11%)
Gastrointestinal disorders
Diarrhoea	3	(38%)	1	(13%)	2	(22%)
Nausea	2	(25%)	1	(13%)	0
Abdominal distension	1	(13%)	1	(13%)	0
Abdominal pain lower	0		1	(13%)	0
Constipation	0		0		1	(11%)
Vomiting	0		1	(13%)	0
Infections
Nasopharyngitis	0		1	(13%)	4	(44%)
Lower respiratory tract infection	0		0		1	(11%)
General disorders
Application site haematoma	2	(25%)	1	(13%)	1	(11%)
Fatigue	1	(13%)	0		0
Mass	1	(13%)	0		0
Tenderness	1	(13%)	0		0
Injury and procedural complications
Thermal burn	1	(13%)	0		1	(11%)
Limb injury	0		0		1	(11%)
Procedural pain	0		1	(13%)	0
Fall	1	(13%)	0		0
Musculoskeletal and connective tissue disorders
Arthralgia	0		1	(13%)	0
Back pain	0		1	(13%)	0
Sensation of heaviness	0		1	(13%)	0
Joint stiffness	1	(13%)	0		0
Muscle spasms	1	(13%)	0		0
Muscular weakness	1	(13%)	0		0
Blood and urine
Blood creatinine increased	0		1	(13%)	0
Urine output increased	0		1	(13%)	0
Psychiatric disorders
Insomnia	0		1	(13%)	0
Sleep disorder	0		1	(13%)	0
Respiratory, thoracic and mediastinal disorders
Cough	0		0		1	(11%)
Dysphonia	0		0		1	(11%)
Epistaxis	1	(13%)	0		0
Skin and subcutaneous tissue disorders
Rash	1	(13%)	1	(13%)	0
Erythema	0		1	(13%)	0
Cardiac disorders
Palpitations	0		1	(13%)	0
Eye disorders
Dry eye	1	(13%)	0		0
Eye pain	1	(13%)	0		0
Metabolism and Nutrition Disorders
Decreased Appetite	1	(13%)	1	(13%)	0